Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jan 22, 2009

Premium

Title: Nucleic Acid Microparticles for Pulmonary Delivery

Number: 20090017124

Filed: April 17, 2008

Lead Inventor: Larry Brown, Baxter Healthcare

The invention, the patent application's abstract states, relates to "microparticle compositions in which the microparticles are made of nucleic acids and non-polymeric cations … suitable for administration to moist or aqueous target locations (e.g., the lung tissue)."

According to the abstract, "the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells."


Title: Inhibition of Brain Enzymes Involved in Cerebral Amyloid Angiopathy and Macular Degeneration

Number: 20090018094

Filed: Nov. 30, 2007

Lead Inventor: Wolff Kirsch, Loma Linda University

The patent application, its abstract states, claims "a method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal [that] involves administering compositions containing siRNA to heme oxygenase-1 or heme oxygenase-2, a matrix metalloproteinase inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient."


Title: Modification of Double-Stranded Ribonucleic Acid Molecules

Number: 20090018097

Filed: May 25, 2006 PCT Filed: May 25, 2006

Lead Inventor: Steven Quay, Nastech Pharmaceutical (MDRNA)

The invention, the patent application's abstract states, comprises "a double-stranded RNA molecule … between about 15 base pairs and about 40 base pairs [long], wherein at least one ribonucleotide of the dsRNA is a 5'-methyl-pyrimidine and/or at least one 2'-O-methyl ribonucleotide." The invention further comprises "a method of improving ribonuclease stability, reducing off-target effects of a double-stranded siRNA molecule, or of reducing interferon responsiveness of a double-stranded siRNA molecule using such dsRNA."


Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA

Number: 20090018321

Filed: June 12, 2008

Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)

"The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene," the patent application's abstract states. "The method involves introducing into the environment of a cell an amount of a double-stranded RNA such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene."


Title: Method of Screening [a] Compound Regulating the Translation of Specific mRNA

Number: 20090019042

Filed: Nov. 18, 2005 PCT Filed: Nov. 18, 2005

Lead Inventor: Shingo Nakamura, Takeda Pharmaceutical

The invention, the patent application's abstract states, "provides a screening method for a compound capable of preventing/treating a particular disease, which comprises a step for selecting one or more mRNAs whose regulation of translation can result in the prevention/treatment of the disease; a step for searching for mRNA(s) having a sequence, in the molecule, capable of assuming a local secondary structure capable of regulating the translation of the mRNA(s) from among the mRNAs selected in [the first step]; a step for selecting a particular sequence from among sequences capable of assuming a local secondary structure in the particular mRNA extracted in [the second step]; [and] a step for confirming that a partial structure capable of interacting with the compound in the particular sequence selected in [the third step] is not present in the region involved in the regulation of the translation of other mRNA, or even if present, is incapable of regulating the translation."

The screening method further involved "a step for bringing an RNA strand comprising a particular sequence confirmed to be not present in the region involved in the regulation of the translation of other mRNA in [the fourth step] and a test compound into contact with each other, and measuring changes in the stability of the secondary structure of the RNA strand," the abstract adds.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.